Oric Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Feb 23, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 23, 2026

ORIC$9.23+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$45,669	$59,406
Short-term investments	235,819	196,554
Prepaid expenses and other current assets	6,978	6,290
Total current assets	288,466	262,250
Long-term investments	110,762	—
Property and equipment, net	2,415	2,924
Other assets	7,247	8,968
Total assets	$408,890	$274,142
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$3,824	$1,548
Accrued liabilities	16,593	23,298
Total current liabilities	20,417	24,846
Other long-term liabilities	4,111	6,174
Total liabilities	24,528	31,020
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024	—	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 98,528,949 and 71,021,855 shares issued and outstanding at December 31, 2025 and 2024, respectively	11	7
Additional paid-in capital	1,075,807	805,510
Accumulated deficit	(692,242)	(562,774)
Accumulated other comprehensive income	786	379
Total stockholders' equity	384,362	243,122
Total liabilities and stockholders' equity	$408,890	$274,142

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.